Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Cervical Cancer, May 2019

Free Subscription


Abstracts

Retrieve all available abstracts of the following 180 articles:
HTML format


 

Single Articles

  1. ZHANG F, Liu J, Xie BB
    Downregulation of microRNA-205 inhibits cell invasion and angiogenesis of cervical cancer through TSLC1-mediated Akt signaling pathway.
    J Cell Physiol. 2019 May 2. doi: 10.1002/jcp.28501.
    Abstract    

    Abstract available

  2. LEE JW, Kim HS, Moon EY
    Thymosin beta-4 is a novel regulator for primary cilium formation by nephronophthisis 3 in HeLa human cervical cancer cells.
    Sci Rep. 2019;9:6849.
    Abstract    

    Abstract available

  3. HOOVER DS, Spears CA, Vidrine DJ, Walker JL, et al
    Smoking Cessation Treatment Needs of Low SES Cervical Cancer Survivors.
    Am J Health Behav. 2019;43:606-620.
    Abstract    

    Abstract available

  4. LIEBERMANN EJ, VanDevanter N, Shirazian T, Frias Guzman N, et al
    Barriers to Cervical Cancer Screening and Treatment in the Dominican Republic: Perspectives of Focus Group Participants in the Santo Domingo Area.
    J Transcult Nurs. 2019 May 3:1043659619846247. doi: 10.1177/1043659619846247.
    Abstract    

    Abstract available

  5. SIMMS KT, Steinberg J, Caruana M, Smith MA, et al
    Towards global elimination of cervical cancer in all groups of women - Authors' reply.
    Lancet Oncol. 2019;20:e239.
    Abstract    



  6. WHOP LJ, Cunningham J, Garvey G, Condon JR, et al
    Towards global elimination of cervical cancer in all groups of women.
    Lancet Oncol. 2019;20:e238.
    Abstract    



  7. KUMAR P, Gupta S, Das AM, Das BC, et al
    Towards global elimination of cervical cancer in all groups of women.
    Lancet Oncol. 2019;20:e237.
    Abstract    



  8. SMITH A, Baines N, Memon S, Fitzgerald N, et al
    Moving toward the elimination of cervical cancer: modelling the health and economic benefits of increasing uptake of human papillomavirus vaccines.
    Curr Oncol. 2019;26:80-84.
    Abstract    

    Abstract available

  9. SUN B, Zhang Y, Zhou L, Yin L, et al
    The proliferation of cervical cancer is promoted by miRNA-125b through the regulation of the HMGA1.
    Onco Targets Ther. 2019;12:2767-2776.
    Abstract    

    Abstract available

  10. SIESTO G, Finco A, Portuesi RAV, Romano F, et al
    SURVIVAL OUTCOMES OF ROBOTIC RADICAL HYSTERECTOMY FOR EARLY STAGE CERVICAL CANCER: A 9-YEAR STUDY.
    Int J Med Robot. 2019 Apr 30:e2003. doi: 10.1002/rcs.2003.
    Abstract    

    Abstract available

  11. KORI M, Gov E, Arga KY
    Novel Genomic Biomarker Candidates for Cervical Cancer As Identified by Differential Co-Expression Network Analysis.
    OMICS. 2019 Apr 30. doi: 10.1089/omi.2019.0025.
    Abstract    

    Abstract available

  12. GONG Y, Wan JH, Zou W, Lian GY, et al
    MiR-29a inhibits invasion and metastasis of cervical cancer via modulating methylation of tumor suppressor SOCS1.
    Future Oncol. 2019 Apr 30. doi: 10.2217/fon-2018-0497.
    Abstract    

    Abstract available

  13. WANG H, He QJ, Han L, Cheng YL, et al
    [Risk Factors Associated with Intraoperative Blood Loss in Patients with Early Cervical Cancer].
    Sichuan Da Xue Xue Bao Yi Xue Ban. 2019;50:115-118.
    Abstract    

    Abstract available

  14. SIMON MA, Tom LS, Leung I, Wong E, et al
    The Chinatown Patient Navigation Program: Adaptation and Implementation of Breast and Cervical Cancer Patient Navigation in Chicago's Chinatown.
    Health Serv Insights. 2019;12:1178632919841376.
    Abstract    

    Abstract available

  15. BLAKE J
    What's needed for Canada's cervical cancer endgame?
    CMAJ. 2019;191:E481.
    Abstract    



  16. LIU Y, Qian J, Sun Z, Zhangsun D, et al
    Cervical Cancer Correlates with the Differential Expression of Nicotinic Acetylcholine Receptors and Reveals Therapeutic Targets.
    Mar Drugs. 2019;17.
    Abstract    

    Abstract available

  17. SUTEU O, Blaga ML, Nygard M, Leinonen MK, et al
    Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
    Eur J Cancer Prev. 2019 Apr 26. doi: 10.1097/CEJ.0000000000000522.
    Abstract    

    Abstract available

  18. ZHU Y, Liu B, Zhang P, Zhang J, et al
    LncRNA TUSC8 inhibits the invasion and migration of cervical cancer cells via miR-641/PTEN axis.
    Cell Biol Int. 2019 Apr 29. doi: 10.1002/cbin.11152.
    Abstract    

    Abstract available

  19. LIANG Y, Lu B, Zhao P, Lu W, et al
    Increased circulating GrMyeloid-derived suppressor cells correlated with tumor burden and survival in locally advanced cervical cancer patient.
    J Cancer. 2019;10:1341-1348.
    Abstract    

    Abstract available

  20. DHANASEKARAN K, Verma C, Kumar V, Hariprasad R, et al
    Cervical Cancer Screening Services at Tertiary Healthcare Facility: An Alternative Approach
    Asian Pac J Cancer Prev. 2019;20:1265-1269.
    Abstract    

    Abstract available

  21. DHAHER EA
    Knowledge, Attitudes and Practices of Women in the Southern Region of Saudi Arabia Regarding Cervical Cancer and the Pap Smear Test
    Asian Pac J Cancer Prev. 2019;20:1177-1184.
    Abstract    

    Abstract available

  22. BALMAGAMBETOVA SK, Tinelli A, Urazayev ON, Sakieva KZ, et al
    HPV Types Distribution in General Female Population and in Women Diagnosed with Cervical Cancer Across Western Kazakhstan
    Asian Pac J Cancer Prev. 2019;20:1089-1096.
    Abstract    

    Abstract available

  23. MOHD ISA SA, Md Salleh MS, Ismail MP, Hairon SM, et al
    ADAM9 Expression in Uterine Cervical Cancer and Its Associated Factors
    Asian Pac J Cancer Prev. 2019;20:1081-1087.
    Abstract    

    Abstract available

  24. ISAKOVA J, Vinnikov D, Bukuev N, Talaibekova E, et al
    capital TE, Cyrilliccapital ER, Cyrillic53 Codon 72 Polymorphism and Human Papilloma Virus-Associated Cervical Cancer in Kyrgyz Women
    Asian Pac J Cancer Prev. 2019;20:1057-1062.
    Abstract    

    Abstract available

  25. DING L, Zhang H
    Circ-ATP8A2 promotes cell proliferation and invasion as a ceRNA to target EGFR by sponging miR-433 in cervical cancer.
    Gene. 2019;705:103-108.
    Abstract    

    Abstract available

  26. ZHANG T, Xue X, Peng H
    Therapeutic Delivery of miR-29b Enhances Radiosensitivity in Cervical Cancer.
    Mol Ther. 2019 Apr 11. pii: S1525-0016(19)30168.
    Abstract    

    Abstract available

  27. LIANG P, Sun G, Wei S
    Application of Deep Learning Algorithm in Cervical Cancer MRI Image Segmentation Based on Wireless Sensor.
    J Med Syst. 2019;43:156.
    Abstract    

    Abstract available

  28. LEE N, Kim SI, Lee M, Kim HS, et al
    Bevacizumab Efficacy and Recurrence Pattern of Persistent and Metastatic Cervical Cancer.
    In Vivo. 2019;33:863-868.
    Abstract    

    Abstract available

  29. YAGI A, Ueda Y, Ikeda S, Sekine M, et al
    Evaluation of future cervical cancer risk in Japan, based on birth year.
    Vaccine. 2019 Apr 23. pii: S0264-410X(19)30508.
    Abstract    

    Abstract available

  30. TAN MBBS MRCP FRCR MD LT, Tanderup PhD K, Kirisits PhD C, de Leeuw PhD A, et al
    Image-guided Adaptive Radiotherapy in Cervical Cancer.
    Semin Radiat Oncol. 2019;29:284-298.
    Abstract    

    Abstract available

  31. FU S, Fokom Domgue J, Chan W, Zhao B, et al
    Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas.
    J Low Genit Tract Dis. 2019;23:102-109.
    Abstract    

    Abstract available

  32. LI S, Zhang W, Jiang K, Shan H, et al
    Nanobody against the E7 oncoprotein of human papillomavirus 16.
    Mol Immunol. 2019;109:12-19.
    Abstract    

    Abstract available

  33. ZHAO Y, Li M, Li Y, Lv Q, et al
    Evaluation of Folate Receptor-Mediated Cervical Dyeing as a Method for Detection of Cervical Lesions.
    J Low Genit Tract Dis. 2019;23:133-137.
    Abstract    

    Abstract available

  34. PARK JY
    Additional benefit of minimally invasive surgery to improve functional outcomes after radical hysterectomy.
    J Gynecol Oncol. 2019;30:e64.
    Abstract    



  35. TANGJITGAMOL S
    Trends of uterine cancer incidence: a projection from the past to the future.
    J Gynecol Oncol. 2019;30:e36.
    Abstract    



  36. XIAO YP, Tao X, Zhao CY, Qu YQ, et al
    [Relationship between various histological status of margins of LEEP and residual HSIL or worse at hysterectomy following conization].
    Zhonghua Fu Chan Ke Za Zhi. 2019;54:19-23.
    Abstract    

    Abstract available

  37. SONG GY, Wang W, Wang YP, Liu M, et al
    [Application and clinical significance of Silva pattern system in invasive endocervical adenocarcinoma].
    Zhonghua Fu Chan Ke Za Zhi. 2019;54:13-18.
    Abstract    

    Abstract available

  38. WANG LQ, Wang Y, Jin W, Cao C, et al
    [Clinicopathological analysis of cervical basaloid squamous cell carcinoma].
    Zhonghua Fu Chan Ke Za Zhi. 2019;54:7-12.
    Abstract    

    Abstract available

  39. HUH WK, Papagiannakis E, Gold MA
    Observed Colposcopy Practice in US Community-Based Clinics: The Retrospective Control Arm of the IMPROVE-COLPO Study.
    J Low Genit Tract Dis. 2019;23:110-115.
    Abstract    

    Abstract available

  40. WANG Q, Ma X, Zhang X, Ong JJ, et al
    Human papillomavirus infection and associated factors for cervical intraepithelial neoplasia in women living with HIV in China: a cross-sectional study.
    Sex Transm Infect. 2019;95:140-144.
    Abstract    

    Abstract available

  41. ZHAO D, Li B, Wang Y, Liu S, et al
    Clinical Outcomes in Early Cervical Cancer Patients Treated with Nerve Plane-Sparing Laparoscopic Radical Hysterectomy.
    J Minim Invasive Gynecol. 2019 May 7. pii: S1553-4650(19)30213.
    Abstract    

    Abstract available

  42. YIN F, He H, Zhang B, Zheng J, et al
    Effect of Deubiquitinase Ovarian Tumor Domain-Containing Protein 5 (OTUD5) on Radiosensitivity of Cervical Cancer by Regulating the Ubiquitination of Akt and its Mechanism.
    Med Sci Monit. 2019;25:3469-3475.
    Abstract    

    Abstract available

  43. TANGJITGAMOL S, Tharavichitkul E, Tovanabutra C, Rongsriyam K, et al
    A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial.
    J Gynecol Oncol. 2019 Apr 10. pii: 30.e82. doi: 10.3802/jgo.2019.
    Abstract    

    Abstract available

  44. VALE DB, Cavalcante LA, Andrade LALA, Teixeira JC, et al
    Stage and histology of cervical cancer in women under 25 years old.
    J Gynecol Oncol. 2019 Feb 26. pii: 30.e55. doi: 10.3802/jgo.2019.
    Abstract    

    Abstract available

  45. NASEEM A, Bhat ZI, Kalaiarasan P, Kumar B, et al
    Assessment of epigenetic alterations and in silico analysis of mutation affecting PTEN expression among Indian cervical cancer patients.
    J Cell Biochem. 2019 May 9. doi: 10.1002/jcb.28856.
    Abstract    

    Abstract available

  46. BING EG, Parham GP, Cuevas A, Fisher B, et al
    Using Low-Cost Virtual Reality Simulation to Build Surgical Capacity for Cervical Cancer Treatment.
    J Glob Oncol. 2019;5:1-7.
    Abstract    

    Abstract available

  47. HOU X, Wang W, Zhang F, Hu K, et al
    Stereotactic body radiation therapy for oligometastatic pulmonary tumors from cervical cancer.
    Asia Pac J Clin Oncol. 2019 May 8. doi: 10.1111/ajco.13159.
    Abstract    

    Abstract available

  48. YI D, Kong L, Zhao Y
    Contrast-Enhancing Snapshot Narrow-Band Imaging Method for Real-Time Computer-Aided Cervical Cancer Screening.
    J Digit Imaging. 2019 May 8. pii: 10.1007/s10278-019-00215.
    Abstract    

    Abstract available

  49. PAPATLA K, Houck KL, Hernandez E, Chu C, et al
    Second primary uterine malignancies after radiation therapy for cervical cancer.
    Arch Gynecol Obstet. 2019 May 8. pii: 10.1007/s00404-019-05187.
    Abstract    

    Abstract available

  50. MISHRA GA, Pimple SA, Gupta SD
    Evaluation of cytology as secondary triage in visual inspection after application of 4% acetic acid-based cervical cancer screening program.
    South Asian J Cancer. 2019;8:102-107.
    Abstract    

    Abstract available

  51. SEBAN RD, Robert C, Dercle L, Yeh R, et al
    Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy.
    Oncoimmunology. 2019;8:e1574197.
    Abstract    

    Abstract available

  52. KIM DH, Kim HM, Huong PTT, Han HJ, et al
    Enhanced anticancer effects of a methylation inhibitor by inhibiting a novel DNMT1 target, CEP 131, in cervical cancer.
    BMB Rep. 2019 May 9. pii: 4547.
    Abstract    

    Abstract available

  53. ZHAO X, Zhao S, Hu S, Zhao K, et al
    Role of Human Papillomavirus DNA Load in Predicting the Long-term Risk of Cervical Cancer: A 15-Year Prospective Cohort Study in China.
    J Infect Dis. 2019;219:215-222.
    Abstract    

    Abstract available

  54. ZAMORANO AS, Barnoya J, Gharzouzi E, Chrisman Robbins C, et al
    Treatment Compliance as a Major Barrier to Optimal Cervical Cancer Treatment in Guatemala.
    J Glob Oncol. 2019;5:1-5.
    Abstract    

    Abstract available

  55. BRITO AET, Matushita C, Esteves F, Gomes G, et al
    Cervical cancer - staging and restaging with 18F-FDG PET/CT.
    Rev Assoc Med Bras (1992). 2019;65:568-575.
    Abstract    

    Abstract available

  56. PORSCH LM, Zhang H, Dayananda I, Dean G, et al
    Comparing Receipt of Cervical Cancer Screening and Completion of Human Papillomavirus Vaccination Using a New Construct of Sexual Orientation: A Serial Cross-Sectional Study.
    LGBT Health. 2019 May 8. doi: 10.1089/lgbt.2018.0196.
    Abstract    

    Abstract available

  57. WU W, Sui J, Liu T, Yang S, et al
    Integrated analysis of two-lncRNA signature as a potential prognostic biomarker in cervical cancer: a study based on public database.
    PeerJ. 2019;7:e6761.
    Abstract    

    Abstract available

  58. PRODROMIDOU A, Iavazzo C, Fotiou A, Psomiadou V, et al
    Short- and long term outcomes after abdominal radical trachelectomy versus radical hysterectomy for early stage cervical cancer: a systematic review of the literature and meta-analysis.
    Arch Gynecol Obstet. 2019 May 6. pii: 10.1007/s00404-019-05176.
    Abstract    

    Abstract available

  59. GUO Y, Ma D, Jia FS, Liu J, et al
    [Proliferation of MicroRNA-365 and E74-like Factor 4 in Cervical Cancer Cells and Its Clinical Significance].
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019;41:220-227.
    Abstract    

    Abstract available

  60. ZHA H, Li X, Sun H, Duan L, et al
    S100A9 promotes the proliferation and migration of cervical cancer cells by inducing epithelialmesenchymal transition and activating the Wnt/betacatenin pathway.
    Int J Oncol. 2019 May 2. doi: 10.3892/ijo.2019.4793.
    Abstract    

    Abstract available

  61. ZHOU Y, Wang W, Wei R, Jiang G, et al
    Serum bradykinin levels as a diagnostic marker in cervical cancer with a potential mechanism to promote VEGF expression via BDKRB2.
    Int J Oncol. 2019 May 2. doi: 10.3892/ijo.2019.4792.
    Abstract    

    Abstract available

  62. BOSSLER F, Hoppe-Seyler K, Hoppe-Seyler F
    PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  63. PAN Q, Xu J, Ma L
    Simvastatin enhances chemotherapy in cervical cancer via inhibition of multiple prenylation-dependent GTPases-regulated pathways.
    Fundam Clin Pharmacol. 2019 May 6. doi: 10.1111/fcp.12479.
    Abstract    

    Abstract available

  64. RODRIGUEZ J, Castro JC, Beltran M, Forero O, et al
    Simultaneous Metastasis from Cervical Cancer to the Kidney and Paraspinal Muscle: A Case Report.
    Cureus. 2019;11:e4148.
    Abstract    

    Abstract available

  65. AL-MADANI W, Ahmed AE, Arabi H, Al Khodairy S, et al
    Modelling risk assessment for cervical cancer in symptomatic Saudi women.
    Saudi Med J. 2019;40:447-451.
    Abstract    

    Abstract available

  66. SU J, Zhang F, Li X, Liu Z, et al
    Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
    Biochem Biophys Res Commun. 2019 May 2. pii: S0006-291X(19)30643.
    Abstract    

    Abstract available

  67. NYAMBE A, Kampen JK, Baboo SK, Van Hal G, et al
    Knowledge, attitudes and practices of cervical cancer prevention among Zambian women and men.
    BMC Public Health. 2019;19:508.
    Abstract    

    Abstract available

  68. IFEDIORA CO
    Re-thinking breast and cervical cancer preventive campaigns in developing countries: the case for interventions at high schools.
    BMC Public Health. 2019;19:503.
    Abstract    

    Abstract available

  69. PIKALA M, Burzynska M, Maniecka-Bryla I
    Years of Life Lost Due to Cervical Cancer in Poland in 2000 to 2015.
    Int J Environ Res Public Health. 2019;16.
    Abstract    

    Abstract available

  70. AKHTAR A, Ghali L, Wang SX, Bell C, et al
    Optimisation of Folate-Mediated Liposomal Encapsulated Arsenic Trioxide for Treating HPV-Positive Cervical Cancer Cells In Vitro.
    Int J Mol Sci. 2019;20.
    Abstract    

    Abstract available

  71. KOTOWSKI A, Kotowska M, Warzyszynska A, Szymusik I, et al
    Cervical cancer - causes and prevention of hpv infections in the opinions of young polish women: a cross-sectional survey.
    Wiad Lek. 2019;72:327-335.
    Abstract    

    Abstract available

  72. LEE CL, Huang KG
    Clinical trial should be more rigorous.
    Taiwan J Obstet Gynecol. 2019;58:306-307.
    Abstract    



  73. AHMED O, Nguyen VD, Ginsburg M, Barry P, et al
    CT-Guided Placement of a Polyethylene Glycol Hydrogel in Brachytherapy for Gynecologic Malignancy to Limit Nontarget Organ Toxicity.
    J Vasc Interv Radiol. 2019;30:469-471.
    Abstract    



  74. BOLHASSANI A, Shahbazi S, Agi E, Haghighipour N, et al
    Modified DCs and MSCs with HPV E7 antigen and small Hsps: Which one is the most potent strategy for eradication of tumors?
    Mol Immunol. 2019;108:102-110.
    Abstract    

    Abstract available

  75. SUL 'AIN MD, Zakaria F, Johan MF
    Anti-Proliferative Effects of Methanol and Water Extracts of Pyrrosia piloselloides on the Hela Human Cervical Carcinoma Cell Line
    Asian Pac J Cancer Prev. 2019;20:185-192.
    Abstract    

    Abstract available

  76. KE Y, Al Aboody MS, Alturaiki W, Alsagaby SA, et al
    Photosynthesized gold nanoparticles from Catharanthus roseus induces caspase-mediated apoptosis in cervical cancer cells (HeLa).
    Artif Cells Nanomed Biotechnol. 2019;47:1938-1946.
    Abstract    

    Abstract available

  77. WANG Q, Ding J, Nan G, Lyu Y, et al
    LncRNA NOC2L-4.1 functions as a tumor oncogene in cervical cancer progression by regulating the miR-630/YAP1 pathway.
    J Cell Biochem. 2019 May 17. doi: 10.1002/jcb.28949.
    Abstract    

    Abstract available

  78. BUYUKKOROGLU G, Senel B, Yenilmez E
    Vaginal Suppositories with siRNA and Paclitaxel-Incorporated Solid Lipid Nanoparticles for Cervical Cancer: Preparation and In Vitro Evaluation.
    Methods Mol Biol. 2019;1974:303-328.
    Abstract    

    Abstract available

  79. RIM SH, Allaire BT, Ekwueme DU, Miller JW, et al
    Cost-effectiveness of breast cancer screening in the National Breast and Cervical Cancer Early Detection Program.
    Cancer Causes Control. 2019 May 16. pii: 10.1007/s10552-019-01178.
    Abstract    

    Abstract available

  80. ARROSSI S, Paolino M, Laudi R, Gago J, et al
    Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study.
    Lancet Glob Health. 2019;7:e772-e783.
    Abstract    

    Abstract available

  81. ARBYN M, de Sanjose S, Weiderpass E
    HPV-based cervical cancer screening, including self-sampling, versus screening with cytology in Argentina.
    Lancet Glob Health. 2019;7:e688-e689.
    Abstract    



  82. YU J, Zhao Y, Liu C, Hu B, et al
    Synergistic anti-tumor effect of paclitaxel and miR-34a combined with ultrasound microbubbles on cervical cancer in vivo and in vitro.
    Clin Transl Oncol. 2019 May 15. pii: 10.1007/s12094-019-02131.
    Abstract    

    Abstract available

  83. FAN MJ, Zou YZ, He PJ, Zhang S, et al
    Long non-coding RNA SPRY4-IT1 promotes epithelial-mesenchymal transition of cervical cancer by regulating the miR-101-3p/ZEB1 axis.
    Biosci Rep. 2019 May 15. pii: BSR20181339. doi: 10.1042/BSR20181339.
    Abstract    

    Abstract available

  84. RATIU D, Luncescu C, Morgenstern B, Eichler C, et al
    Comparison of Minimally Invasive Surgery and Abdominal Surgery Among Patients With Cervical Cancer.
    Anticancer Res. 2019;39:2661-2664.
    Abstract    

    Abstract available

  85. LIM SC, Yoo CW
    Current status of and perspectives on cervical cancer screening in Korea.
    J Pathol Transl Med. 2019 May 16. pii: jptm.2019.
    Abstract    

    Abstract available

  86. LAWAL IO, Ololade KO, Popoola GO, Ankrah AO, et al
    18F-FDG-PET/CT imaging of uterine cervical cancer recurrence in women with and without HIV infection.
    Q J Nucl Med Mol Imaging. 2019 May 8. pii: S1824-4785.19.03156.
    Abstract    

    Abstract available

  87. DE SILVA AHW, Samarawickrema N, Kasturiratne A, Skinner SR, et al
    Awareness of human papillomavirus, cervical cancer and its prevention among primigravid antenatal clinic attendees in a tertiary care hospital in Sri Lanka: a cross-sectional study.
    Sex Health. 2019 May 15. pii: SH18080. doi: 10.1071/SH18080.
    Abstract    

    Abstract available

  88. WONG CL, So WKW, Chan DNS, Choi KC, et al
    A community health worker-led multimedia intervention to increase cervical cancer screening uptake among South Asian women: study protocol for a cluster randomized wait-list controlled trial.
    Trials. 2019;20:270.
    Abstract    

    Abstract available

  89. KILIC A, Tastan S, Guvenc G, Akyuz A, et al
    Breast and cervical cancer screening for women with physical disabilities: A qualitative study of experiences and barriers.
    J Adv Nurs. 2019 May 14. doi: 10.1111/jan.14048.
    Abstract    

    Abstract available

  90. SONG W, Wang J, Liu H, Zhu C, et al
    Effects of LncRNA Lnc-LIF-AS on cell proliferation, migration and invasion in a human cervical cancer cell line.
    Cytokine. 2019;120:165-175.
    Abstract    

    Abstract available

  91. RYAN M, Marlow L, Waller J
    Socio-demographic correlates of cervical cancer risk factor knowledge among screening non-participants in Great Britain.
    Prev Med. 2019 May 11. pii: S0091-7435(19)30165.
    Abstract    

    Abstract available

  92. DARJ E, Chalise P, Shakya S
    Barriers and facilitators to cervical cancer screening in Nepal: A qualitative study.
    Sex Reprod Healthc. 2019;20:20-26.
    Abstract    

    Abstract available

  93. ADEGBOYEGA A, Aleshire M, Dignan M, Hatcher J, et al
    Spousal support and knowledge related to cervical cancer screening: Are Sub-Saharan African immigrant men interested?
    Health Care Women Int. 2019 May 14:1-17. doi: 10.1080/07399332.2019.1615914.
    Abstract    

    Abstract available

  94. SHEN H, Wang L, Xiong J, Ren C, et al
    Long non-coding RNA CCAT1 promotes cervical cancer cell proliferation and invasion by regulating the miR-181a-5p/MMP14 axis.
    Cell Cycle. 2019 May 14:1-12. doi: 10.1080/15384101.2019.1609829.
    Abstract    

    Abstract available

  95. GUO J, Chen M, Ai G, Mao W, et al
    Hsa_circ_0023404 enhances cervical cancer metastasis and chemoresistance through VEGFA and autophagy signaling by sponging miR-5047.
    Biomed Pharmacother. 2019;115:108957.
    Abstract    

    Abstract available

  96. WENTZENSEN N, Clarke MA, Bremer R, Poitras N, et al
    Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program.
    JAMA Intern Med. 2019 May 13. pii: 2732692. doi: 10.1001/jamainternmed.2019.0306
    Abstract    

    Abstract available

  97. SAWAYA GF, Sanstead E, Alarid-Escudero F, Smith-McCune K, et al
    Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis.
    JAMA Intern Med. 2019 May 13. pii: 2732691. doi: 10.1001/jamainternmed.2019.0299
    Abstract    

    Abstract available

  98. FELDMAN S
    Screening Options for Preventing Cervical Cancer.
    JAMA Intern Med. 2019 May 13. pii: 2732687. doi: 10.1001/jamainternmed.2019.0298
    Abstract    



  99. WANG XW, Zhang W
    Long non-coding RNA cancer susceptibility candidate 2 inhibits the cell proliferation, invasion and angiogenesis of cervical cancer through the MAPK pathway.
    Eur Rev Med Pharmacol Sci. 2019;23:3261-3269.
    Abstract    

    Abstract available

  100. ZHANG XF, An MZ, Ma YP, Lu YM, et al
    Regulatory effects of CCDC3 on proliferation, migration, invasion and EMT of human cervical cancer cells.
    Eur Rev Med Pharmacol Sci. 2019;23:3217-3224.
    Abstract    

    Abstract available

  101. WANG H, Lakshmipriya T, Chen Y, Gopinath SCB, et al
    Squamous Cell Carcinoma Biomarker Sensing on a Strontium Oxide-Modified Interdigitated Electrode Surface for the Diagnosis of Cervical Cancer.
    Biomed Res Int. 2019;2019:2807123.
    Abstract    

    Abstract available

  102. TSURUOKA S, Kataoka M, Hamamoto Y, Tokumasu A, et al
    Tumor growth patterns on magnetic resonance imaging and treatment outcomes in patients with locally advanced cervical cancer treated with definitive radiotherapy.
    Int J Clin Oncol. 2019 May 11. pii: 10.1007/s10147-019-01457.
    Abstract    

    Abstract available

  103. ZHU LX, Liu Q, Hua YF, Yang N, et al
    Systematic Profiling and Evaluation of Structure-based Kinase-Inhibitor Interactome in Cervical Cancer by Integrating In Silico Analyses and In Vitro Assays at Molecular and Cellular Levels.
    Comput Biol Chem. 2019;80:324-332.
    Abstract    

    Abstract available

  104. LV Q, Wang Y, Su C, Lakshmipriya T, et al
    Human papilloma virus DNA-biomarker analysis for cervical cancer: Signal enhancement by gold nanoparticle-coupled tetravalent streptavidin-biotin strategy.
    Int J Biol Macromol. 2019 May 9. pii: S0141-8130(19)31983.
    Abstract    

    Abstract available

  105. CHIDO-AMAJUOYI OG, Shete S
    Prevalence of Abnormal Cervical Cancer Screening Outcomes among Screening Compliant Women in the United States.
    Am J Obstet Gynecol. 2019 May 9. pii: S0002-9378(19)30579.
    Abstract    



  106. BIXEL KL, Fowler JM
    Fertility-sparing surgery for early-stage cervical cancer: does surgical approach have an impact on disease outcomes?
    Am J Obstet Gynecol. 2019;220:417-419.
    Abstract    



  107. GREMA BA, Aliyu I, Michael GC, Mafala MB, et al
    Diagnosing Premalignant Lesions of Uterine Cervix in A ResourceConstraint Setting: A Narrative Review.
    West Afr J Med. 2019;36:48-53.
    Abstract    

    Abstract available

  108. GIRISH B, Davis AA
    Chronic uterine inversion with malignancy mimicking carcinoma cervix.
    BMJ Case Rep. 2019;12.
    Abstract    

    Abstract available

  109. SATIBI S, Andayani TM, Endarti D, Suwantara IPT, et al
    Comparison of Real Cost Versus the Indonesian Case Base Groups (INA-CBGs) Tariff Rates Among Patients of High- Incidence Cancers Under the National Health Insurance Scheme
    Asian Pac J Cancer Prev. 2019;20:117-122.
    Abstract    

    Abstract available

  110. NAUMANN RW
    Minimally Invasive Radical Hysterectomy Has Many Benefits Compared with Open Radical Hysterectomy: Will the LACC Trial Cause the Premature Demise of This Procedure?
    J Minim Invasive Gynecol. 2019;26:379-380.
    Abstract    



  111. FRANK WOLF M, Elon R, Hassan D, Zarfati D, et al
    Colposcopy in Evaluating Bleeding During the Second and Third Trimesters: Short-Term and Postpartum Implications.
    Gynecol Obstet Invest. 2019;84:154-158.
    Abstract    

    Abstract available

  112. KAHRAMANOGLU I, Demirkiran F, Turan H, Bese T, et al
    The use of colposcopic punch biopsy in the management of abnormal cervical cytology: a 5-year retrospective audit.
    J Obstet Gynaecol. 2019;39:110-114.
    Abstract    

    Abstract available

  113. OTANI S, Fujii T, Kukimoto I, Yamamoto N, et al
    Cytokine expression profiles in cervical mucus from patients with cervical cancer and its precursor lesions.
    Cytokine. 2019;120:210-219.
    Abstract    

    Abstract available

  114. SUNDSTROM B, Smith E, Delay C, Luque JS, et al
    A reproductive justice approach to understanding women's experiences with HPV and cervical cancer prevention.
    Soc Sci Med. 2019;232:289-297.
    Abstract    

    Abstract available

  115. COUDRAY M, Kiplagat S
    Bacterial Vaginosis and the risk of human papillomavirus and cervical cancer.
    Am J Obstet Gynecol. 2019 May 20. pii: S0002-9378(19)30674.
    Abstract    



  116. BRUSSELAERS N, Verstraelen H
    Reply to letter on article entitled "Vaginal dysbiosis, and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis".
    Am J Obstet Gynecol. 2019 May 20. pii: S0002-9378(19)30673.
    Abstract    



  117. CAO Z, Zhang G, Xie C, Zhou Y, et al
    MiR-34b regulates cervical cancer cell proliferation and apoptosis.
    Artif Cells Nanomed Biotechnol. 2019;47:2042-2047.
    Abstract    

    Abstract available

  118. CHOTHIPHIRAT A, Nittayaboon K, Kanokwiroon K, Srisawat T, et al
    Anticancer Potential of Fruit Extracts from Vatica diospyroides Symington Type SS and Their Effect on Program Cell Death of Cervical Cancer Cell Lines.
    ScientificWorldJournal. 2019;2019:5491904.
    Abstract    

    Abstract available

  119. ZHANG W, Chen C, Liu P, Li W, et al
    Impact of pelvic MRI in routine clinical practice on staging of IB1-IIA2 cervical cancer.
    Cancer Manag Res. 2019;11:3603-3609.
    Abstract    

    Abstract available

  120. LI N, Cui T, Guo W, Wang D, et al
    MiR-155-5p accelerates the metastasis of cervical cancer cell via targeting TP53INP1.
    Onco Targets Ther. 2019;12:3181-3196.
    Abstract    

    Abstract available

  121. WEI M, Yu H, Zhang Y, Zeng J, et al
    Decreased expression of aquaporin 1 correlates with clinicopathological features of patients with cervical cancer.
    Onco Targets Ther. 2019;12:2843-2851.
    Abstract    

    Abstract available

  122. WANG A, Cui G, Jin C, Wang Y, et al
    Multicenter research on tumor and pregnancy outcomes in patients with early-stage cervical cancer after fertility-sparing surgery.
    J Int Med Res. 2019 May 22:300060519845974. doi: 10.1177/0300060519845974.
    Abstract    

    Abstract available

  123. SUN W, Shen NM, Fu SL
    Involvement of lncRNA-mediated signaling pathway in the development of cervical cancer.
    Eur Rev Med Pharmacol Sci. 2019;23:3672-3687.
    Abstract    

    Abstract available

  124. ZHANG YY, Li M, Xu YD, Shang J, et al
    LncRNA SNHG14 promotes the development of cervical cancer and predicts poor prognosis.
    Eur Rev Med Pharmacol Sci. 2019;23:3664-3671.
    Abstract    

    Abstract available

  125. ZHENG JJ, Du XJ, Wang HP, Zhou LY, et al
    Long non-coding RNA 00152 promotes cell proliferation in cervical cancer via regulating miR-216b-5p/HOXA1 axis.
    Eur Rev Med Pharmacol Sci. 2019;23:3654-3663.
    Abstract    

    Abstract available

  126. PAN ZX, Zhang XY, Chen SR, Li CZ, et al
    Upregulated exosomal miR-221/222 promotes cervical cancer via repressing methyl-CpG-binding domain protein 2.
    Eur Rev Med Pharmacol Sci. 2019;23:3645-3653.
    Abstract    

    Abstract available

  127. NAKALEMBE M, Makanga P, Mubiru F, Swanson M, et al
    Prevalence, correlates, and predictive value of high-risk human papillomavirus mRNA detection in a community-based cervical cancer screening program in western Uganda.
    Infect Agent Cancer. 2019;14:14.
    Abstract    

    Abstract available

  128. LIN Y, Zhai H, Ouyang Y, Lu Z, et al
    Knockdown of PKM2 enhances radiosensitivity of cervical cancer cells.
    Cancer Cell Int. 2019;19:129.
    Abstract    

    Abstract available

  129. YANG L, Liu L, Zhu YH, Wang BB, et al
    Neuropilin-1 is associated with the prognosis of cervical cancer in Henan Chinese population.
    Onco Targets Ther. 2019;12:2911-2920.
    Abstract    

    Abstract available

  130. OUYANG P, An W, Chen R, Zhang H, et al
    IL-37 promotes cell apoptosis in cervical cancer involving Bim upregulation.
    Onco Targets Ther. 2019;12:2703-2712.
    Abstract    

    Abstract available

  131. ITO K, Kito S, Nakajima Y, Shimizuguchi T, et al
    Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study.
    Jpn J Clin Oncol. 2019 May 21. pii: 5492757. doi: 10.1093.
    Abstract    

    Abstract available

  132. OKAZAKI S, Murata K, Noda SE, Kumazaki Y, et al
    Dose-volume parameters and local tumor control in cervical cancer treated with central-shielding external-beam radiotherapy and CT-based image-guided brachytherapy.
    J Radiat Res. 2019 May 21. pii: 5492641. doi: 10.1093.
    Abstract    

    Abstract available

  133. SUBRAMANIAN S, Ekwueme DU, Miller JW, Khushalani JS, et al
    Awardee-specific economic costs of providing cancer screening and health promotional services to medically underserved women eligible in the National Breast and Cervical Cancer Early Detection Program.
    Cancer Causes Control. 2019 May 20. pii: 10.1007/s10552-019-01174.
    Abstract    

    Abstract available

  134. RACHMADI L, Siregar NC, Kanoko M, Andrijono A, et al
    Role of Cancer Stem Cell, Apoptotic Factor, DNA Repair, and Telomerase Toward Radiation Therapy Response in Stage IIIB Cervical Cancer.
    Oman Med J. 2019;34:224-230.
    Abstract    

    Abstract available

  135. JIANG L, Hong L, Yang W, Zhao Y, et al
    Co-expression network analysis of the lncRNAs and mRNAs associated with cervical cancer progression.
    Arch Med Sci. 2019;15:754-764.
    Abstract    

    Abstract available

  136. YIN Z, Lou H, Tang H, Ni J, et al
    Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer.
    Radiat Oncol. 2019;14:82.
    Abstract    

    Abstract available

  137. ITO F, Sugiura A, Toyoda S, Itani Y, et al
    Search for conditions to avoid parametrectomy during radical hysterectomy for cervical cancer.
    J Obstet Gynaecol Res. 2019 May 20. doi: 10.1111/jog.13986.
    Abstract    

    Abstract available

  138. PARTANEN VM, Anttila A, Heinavaara S, Pankakoski M, et al
    NordScreen - an interactive tool for presenting cervical cancer screening indicators in the Nordic countries.
    Acta Oncol. 2019 May 20:1-6. doi: 10.1080/0284186X.2019.1615637.
    Abstract    

    Abstract available

  139. CHENG L, Shi X, Huo D, Zhao Y, et al
    MiR-449b-5p regulates cell proliferation, migration and radioresistance in cervical cancer by interacting with the transcription suppressor FOXP1.
    Eur J Pharmacol. 2019 May 16. pii: S0014-2999(19)30338.
    Abstract    

    Abstract available

  140. DING J, Zhang L, Zeng S, Feng T, et al
    Clinically relevant concentration of sevoflurane suppresses cervical cancer growth and migration through targeting multiple oncogenic pathways.
    Biochem Biophys Res Commun. 2019 May 16. pii: S0006-291X(19)30958.
    Abstract    

    Abstract available

  141. TONG J, Yu H, Li J, Zhou J, et al
    Short-term recurrence and distant metastasis following robotic-assisted radical hysterectomy with pelvic lymphadenectomy and chemoradiotherapy for a stage IB1 cervical adenocarcinoma: A case report and literature review.
    Medicine (Baltimore). 2019;98:e15387.
    Abstract    

    Abstract available

  142. CHEN H, Wang H, Liu J, Cheng Q, et al
    Association of the MUTYH Gln324His (CAG/CAC) variant with cervical carcinoma and HR-HPV infection in a Chinese population.
    Medicine (Baltimore). 2019;98:e15359.
    Abstract    

    Abstract available

  143. BRUNO MT, Coco A, Di Pasqua S, Bonanno G, et al
    Management of ASC-US/HPV positive post-menopausal woman.
    Virol J. 2019;16:39.
    Abstract    

    Abstract available

  144. YANG R, Klimentova J, Gockel-Krzikalla E, Ly R, et al
    Combined Transcriptome and Proteome Analysis of Immortalized Human Keratinocytes Expressing Human Papillomavirus 16 (HPV16) Oncogenes Reveals Novel Key Factors and Networks in HPV-Induced Carcinogenesis.
    mSphere. 2019;4.
    Abstract    

    Abstract available

  145. KAWAI S, Torii Y, Kukimoto I, Fujii T, et al
    A case of primary signet-ring cell carcinoma of the cervix containing full genome of human papillomavirus 16.
    Indian J Pathol Microbiol. 2019;62:146-148.
    Abstract    

    Abstract available

  146. HONG S, Xu J, Li Y, Andrade J, et al
    Topoisomerase IIbeta-binding protein 1 activates expression of E2F1 and p73 in HPV-positive cells for genome amplification upon epithelial differentiation.
    Oncogene. 2019;38:3274-3287.
    Abstract    

    Abstract available

  147. GALBRAITH-GYAN KV, Lechuga J, Jenerette CM, Palmer MH, et al
    African-American parents' and daughters' beliefs about HPV infection and the HPV vaccine.
    Public Health Nurs. 2019;36:134-143.
    Abstract    

    Abstract available

  148. HAN W, Zhang S, Qian J, Zhang J, et al
    Redox-responsive Fluorescent Nanoparticles Based on Diselenide-containing AIEgens for Cell Imaging and Selective Cancer Therapy.
    Chem Asian J. 2019;14:1745-1753.
    Abstract    

    Abstract available

  149. SUN H, Chen Y, Chen Y, Liu D, et al
    Primary malignant melanoma of the cervix: 14 cases and literature overview.
    Melanoma Res. 2018 Jul 23. doi: 10.1097/CMR.0000000000000469.
    Abstract    

    Abstract available

  150. MANGOLD BR
    Self-Collected Samples in Cervical Cancer Screening: Results of HPV and Pap Self-Collected Samples Compared to Physician-Obtained Specimens.
    Acta Cytol. 2019 Apr 29:1-6. doi: 10.1159/000499373.
    Abstract    

    Abstract available

  151. SRIVASTAVA AN, Misra JS, Singh U, Khan M, et al
    AgNOR Pleomorphic Count as a Tumor Marker in Cervical Carcinogenesis and Feasibility of Its Introduction in Cervical Cancer Screening Programs to Discriminate High-Risk Cases of Squamous Intraepithelial Lesions of the Cervix.
    Acta Cytol. 2019 May 8:1-8. doi: 10.1159/000498978.
    Abstract    

    Abstract available

  152. PAASO A, Jaakola A, Syrjanen S, Louvanto K, et al
    From HPV Infection to Lesion Progression: The Role of HLA Alleles and Host Immunity.
    Acta Cytol. 2019;63:148-158.
    Abstract    

    Abstract available

  153. ERDEM BE, Cigdem V, Sener G, Bahar M, et al
    Smear cytological features of large cell neuroendocrine carcinoma of the uterine cervix in pregnancy: A case report and review of the literature.
    Diagn Cytopathol. 2018 Nov 21. doi: 10.1002/dc.24106.
    Abstract    

    Abstract available

  154. SENELDIR H, Kir G
    Prevalence of high-risk human papilloma virus in liquid-based cervical samples from Turkish women with normal and abnormal cytology.
    Diagn Cytopathol. 2019;47:100-104.
    Abstract    

    Abstract available

  155. HARBHAJANKA A, Chahar S, Michael CW
    The pathological outcome of ThinPrep Pap tests diagnosed as glandular cell abnormalities alone versus combined glandular and squamous abnormalities.
    Diagn Cytopathol. 2019;47:88-93.
    Abstract    

    Abstract available

  156. KARACA I, Ozturk M, Comba C, Demirayak G, et al
    Does the 'equal management of equal risks' model cause overtreatment in patients with positive cervical cytology results for ASCUS/non-HPV16/18 oncogenic types?
    Diagn Cytopathol. 2019;47:105-109.
    Abstract    

    Abstract available

  157. BARRIGON A, Ziadi S, Jacot-Guillarmod M, Da Silva S, et al
    Nabothian cyst content: A potential pitfall for the diagnosis of invasive cancer on Pap test cytology.
    Diagn Cytopathol. 2019;47:127-129.
    Abstract    

    Abstract available

  158. CROWELL EF, Bazin C, Thurotte V, Elie H, et al
    Adaptation of CytoProcessor for cervical cancer screening of challenging slides.
    Diagn Cytopathol. 2019 May 20. doi: 10.1002/dc.24213.
    Abstract    

    Abstract available

  159. LI M, Hu M, Wang Y, Yang X, et al
    Adjuvant chemoradiotherapy versus radiotherapy in cervical cancer patients with intermediate-risk factors: A systematic review and meta-analysis.
    Eur J Obstet Gynecol Reprod Biol. 2019;238:1-6.
    Abstract    

    Abstract available

  160. NISHIO S, Mikami Y, Tokunaga H, Yaegashi N, et al
    Analysis of gastric-type mucinous carcinoma of the uterine cervix - An aggressive tumor with a poor prognosis: A multi-institutional study.
    Gynecol Oncol. 2019 Jan 29. pii: S0090-8258(19)30063.
    Abstract    

    Abstract available

  161. STOLER MH, Wright TC Jr, Parvu V, Yanson K, et al
    Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, >/=25years of age, with NILM cytology.
    Gynecol Oncol. 2019 Jan 9. pii: S0090-8258(18)31538.
    Abstract    

    Abstract available

  162. WANG J, Du Y, Dong J, Zhou Y, et al
    Clinical significance of genotyping for human papillomavirus (HPV) 16 18/45 combined with cytology in cervical exfoliated cells in HPV oncogenic mRNA-positive women.
    Gynecol Oncol. 2019 Jan 7. pii: S0090-8258(18)31542.
    Abstract    

    Abstract available

  163. LIU JF, Gray KP, Wright AA, Campos S, et al
    Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
    Gynecol Oncol. 2019 May 20. pii: S0090-8258(19)31228.
    Abstract    

    Abstract available

  164. WANG J, Elfstrom KM, Andrae B, Nordqvist Kleppe S, et al
    Cervical cancer case-control audit: Results from routine evaluation of a nationwide cervical screening programme.
    Int J Cancer. 2019 May 20. doi: 10.1002/ijc.32416.
    Abstract    

    Abstract available

  165. JOSHI S, Muwonge R, Kulkarni V, Deodhar K, et al
    Incidence of cervical intraepithelial neoplasia in women infected with human immunodeficiency virus (HIV) with no evidence of disease at baseline: results of a prospective cohort study with up to 6.4 years of follow-up from India.
    Int J Cancer. 2018 Aug 22. doi: 10.1002/ijc.31826.
    Abstract    

    Abstract available

  166. BHATLA N, Berek JS, Cuello Fredes M, Denny LA, et al
    Revised FIGO staging for carcinoma of the cervix uteri.
    Int J Gynaecol Obstet. 2019;145:129-135.
    Abstract    

    Abstract available

  167. ADSUL P, Srinivas V, Gowda S, Nayaka S, et al
    A community-based, cross-sectional study of hrHPV DNA self-sampling-based cervical cancer screening in rural Karnataka, India.
    Int J Gynaecol Obstet. 2019 May 10. doi: 10.1002/ijgo.12859.
    Abstract    

    Abstract available

  168. ZHANG W, Chen C, Liu P, Li W, et al
    Staging early cervical cancer in China: data from a multicenter collaborative.
    Int J Gynecol Cancer. 2019 May 15. pii: ijgc-2019-000263.
    Abstract    

    Abstract available

  169. PLANTE M, van Trommel N, Lheureux S, Oza AM, et al
    FIGO 2018 stage IB2 (2-4 cm) Cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA); Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NEOCON-F). A PMHC, DGOG,
    Int J Gynecol Cancer. 2019 May 17. pii: ijgc-2019-000398.
    Abstract    

    Abstract available

  170. HODGSON A, Olkhov-Mitsel E, Howitt BE, Nucci MR, et al
    International Endocervical Adenocarcinoma Criteria and Classification (IECC): correlation with adverse clinicopathological features and patient outcome.
    J Clin Pathol. 2019;72:347-353.
    Abstract    

    Abstract available

  171. RAO GG
    Surgical Volume and Survival in Cervical Cancer: Bigger Is Better.
    Obstet Gynecol. 2019 May 9. doi: 10.1097/AOG.0000000000003293.
    Abstract    



  172. MATSUO K, Shimada M, Yamaguchi S, Matoda M, et al
    Association of Radical Hysterectomy Surgical Volume and Survival for Early-Stage Cervical Cancer.
    Obstet Gynecol. 2019 May 9. doi: 10.1097/AOG.0000000000003280.
    Abstract    

    Abstract available

  173. PARK S, Kim J, Eom K, Oh S, et al
    microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer.
    BMC Cancer. 2019;19:419.
    Abstract    

    Abstract available

  174. EGLI-GANY D, Spaar Zographos A, Diebold J, Masserey Spicher V, et al
    Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
    BMC Cancer. 2019;19:111.
    Abstract    

    Abstract available

  175. YE J, Cheng XD, Cheng B, Cheng YF, et al
    MiRNA detection in cervical exfoliated cells for missed high-grade lesions in women with LSIL/CIN1 diagnosis after colposcopy-guided biopsy.
    BMC Cancer. 2019;19:112.
    Abstract    

    Abstract available

  176. TAREKEGN AA, Mengistu MY, Mirach TH
    Health professionals' willingness to pay and associated factors for cervical cancer screening program at College of Medicine and Health Sciences, University of Gondar, Northwest Ethiopia.
    PLoS One. 2019;14:e0215904.
    Abstract    

    Abstract available

  177. GETACHEW S, Getachew E, Gizaw M, Ayele W, et al
    Cervical cancer screening knowledge and barriers among women in Addis Ababa, Ethiopia.
    PLoS One. 2019;14:e0216522.
    Abstract    

    Abstract available

  178. PARK S, Lee S, Kim J, Kim G, et al
    Correction: DeltaNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis.
    PLoS One. 2019;14:e0216968.
    Abstract    

    Abstract available

  179. LINDSTROM AK, Hermansson RS, Gustavsson I, Hedlund Lindberg J, et al
    Cervical dysplasia in elderly women performing repeated self-sampling for HPV testing.
    PLoS One. 2018;13:e0207714.
    Abstract    

    Abstract available

  180. KIM HW, Kim DH, Kim YH, Lee EJ, et al
    Clinical nurses' awareness and caring experiences for patients with cervical cancer: A qualitative study.
    PLoS One. 2019;14:e0217201.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cervical Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;